Panoramica di mercato

Breast cancer screening is conducted to detect cancer at an early stage and ensure prompt treatment for patients. Different types of breast cancer depend on the specific cancer cells that become malignant. Breast cancer can affect various parts of the breast, including the ducts and lobes.

The Breast Cancer Screening Test Market is projected to exhibit a Compound Annual Growth Rate (CAGR) of 8.55% during the forecast period.

Several factors contribute to the growth of this market, including increasing awareness of early detection, a rising incidence of breast cancer, and government initiatives and support. Early detection of breast cancer improves outcomes, such as higher survival rates, more treatment options, and enhanced quality of life. The increasing prevalence of breast cancer drives market growth during the forecast period. According to updated data from Breastcancer.org as of July 2022, it is estimated that there will be 287,850 new cases of invasive breast cancer and 51,400 new cases of non-invasive (in situ) breast cancer in the United States. Given the growing demand for breast cancer screening tests in both developed and developing nations, the market is expected to expand during the forecast period.

Inoltre, the proactive efforts of key industry players in developing innovative strategies are expected to propel market growth. For instance, in March 2022, LifeCell introduced the Breast Screen Panel, a comprehensive genetic screening test that assesses women’s risk of developing breast cancer. Such initiatives will drive the adoption of breast cancer screening, thereby stimulating market growth.

However, controversies surrounding mammography and the high cost of screening tests are anticipated to impede market growth.

Segmentazione del mercato

The market is segmented based on various factors, including test and region.

Segmentation by Test
Genomic Test
Imaging Test – Mammograms, Ultrasound, MRI, Tomography, and Other Imaging Tests

Segmentation by Region
North America – United States and Canada United States, Canada, and Mexico
Europe – Regno Unito, Germania, Francia, Italia, Spagna, and Rest of Europe
Asia-Pacific – Cina, Giappone, India, South Korea, Australia, and Rest of Asia-Pacific
Latin America – Brasile, Argentina, and Rest of Latin America
Middle East and Africa – Sud Africa, GCC, and Rest of Middle East and Africa

The imaging segment, specifically the use of imaging tests, held a significant share in the market in 2022, reaching USD 1,894.5 million. It is expected to witness a Compound Annual Growth Rate (CAGR) of 8.7% over the forecast period. The high demand for imaging tests and their advantages over genomic tests contribute to the imaging test segment having the largest share in the overall market.

Within the imaging test segment, mammograms accounted for a substantial share of USD 1,179.18 milioni di euro 2022. This segment is projected to grow at a CAGR of 8.91% during the forecast period. Mammograms are considered the gold standard in screening for breast cancer, making them the primary choice in imaging tests. They are widely recognized as the most reliable method for detecting breast cancer. Governments and healthcare organizations worldwide are actively taking initiatives to improve access to mammography screenings for women between the ages of 50 E 75. For example, the National Cancer Institute (NCI) is funding the tomosynthesis mammographic imaging screening trial (TMIST), a large-scale randomized trial comparing 2-D mammography to 3-D mammography in terms of detecting advanced cancers over a five-year screening period.

Digital breast tomosynthesis, also known as 3-D mammography, is an emerging technology that can enhance the diagnostic accuracy of mammography. This technique combines images taken from multiple angles around the breast to produce a 3-D-like image. The availability of this technology is increasing in clinics, which contributes to its adoption and subsequently drives market growth.

Favorable initiatives related to mammograms are expected to further boost the growth of this segment. For instance, in Australia, the government’s national screening program, Breast Screen Australia, provides free mammograms every two years for women aged 50-74. Cancer Australia has also released regulations emphasizing early diagnosis through breast imaging for the early stages of breast cancer.

Market players are also actively contributing to market growth through product developments. For example, VolparaHealth introduced updated products for its integrated platform at the SBI/ACR Breast Imaging Symposium 2022. Their AI-driven breast software tools enhance mammography quality, reporting, volumetric breast density measurements, and cancer risk assessment. These advancements by industry players play a significant role in accelerating market growth.

In terms of geography, the North American region held a significant share of the market in 2022, reaching USD 1,069.5 million. It is projected to grow at a CAGR of 8.44% during the forecast period. The dominance of North America in the breast cancer screening test market can be attributed to several factors.

Firstly, the region faces a high burden of breast cancer, which drives the demand for screening tests. Additionally, the presence of prominent market players in the region contributes to its market share. Furthermore, the government has implemented screening initiatives to address breast cancer, further boosting the market in North America.

Within the North American region, the United States holds the largest market share. This can be attributed to the increasing incidence rates of breast cancer and the growing awareness among the population regarding the importance of early detection. The developed healthcare infrastructure in the United States also plays a significant role in propelling the market.

In line with efforts to reduce breast cancer-related fatalities, the United States National Breast Cancer Foundation (NBCF) announced funding of over USD 12.4 million for 20 research initiatives in May 2022. Such investments and goals to combat breast cancer are expected to drive the growth of the market in North America over the forecast period.

In Canada, an estimated 28,600 new cases of breast cancer were projected to occur in 2022, accounting for 25% of all newly diagnosed cancers in women in the country, according to a report published in the Canadian Medical Association Journal in May 2022.

Inoltre, awareness campaigns and free breast cancer screening camps conducted in the region contribute to the growth of the market. For example, in October 2022, Pennsylvania Hospital partnered with the American Cancer Society, the Consulate of Mexico in Philadelphia, and Univision 65 to host an annual breast cancer screening event. This event provided free mammograms to uninsured and underinsured women in the Philadelphia community.

Considering these factors, the breast cancer screening market is expected to thrive in North America during the forecast period.

Panorama competitivo

The breast cancer screening test market exhibits a moderate level of competition and is characterized by the presence of several prominent participants. Currently, a few major players dominate the market in terms of market share. However, as awareness about breast cancer screening increases and advancements in screening tests continue to emerge, it is anticipated that additional smaller players will enter the market and potentially gain a substantial share. Among the key market players in the breast cancer screening test market, notable entities include Koninklijke Philips NV, GE Healthcare, Fujifilm Holdings, and Hologic Inc., among others. These companies have established themselves as significant contributors to the market and hold considerable market shares. Their expertise, technological capabilities, and product offerings contribute to their market dominance in the breast cancer screening test segment.

Key Companies Profiled in this report include Carestream Health Inc., F Hoffmann-LA Roche Ltd., Fujifilm Holdings Corporation, GE Healthcare, Hologic, Inc., Koninklijke Philips N.V., Myriad Genetics Inc., Nanostring Technologies Inc., Quest Diagnostics Incorporated, Siemens Healthineers AG.

Recent Industry Developments

Biomerica, Inc. and Walmart have recently signed a general merchandise supplier agreement in June 2022. As part of this agreement, the Aware Breast Self Exam device will now be available for purchase within Walmart’s extensive retail system.

In another development, LifeCell successfully launched the Breast Screen Panel in March 2022. This innovative genetic screening test provides a comprehensive assessment of the risk of breast cancer specifically designed for women. By offering this test, LifeCell aims to provide valuable insights into an individual’s predisposition to breast cancer, enabling early detection and proactive management strategies.

Key Questions Answered

What is the duration of the study period for this market?
What is the rate of growth in the Breast Cancer Screening Test Market?
Which region exhibits the highest growth rate in the Breast Cancer Screening Test Market?
Which region holds the largest market share in the Breast Cancer Screening Test Market?
Who are the primary players in the Breast Cancer Screening Test Market?